Translational Science in Vascular Aging: From Bench to Bedside—Insights from a VascAgeNet Roundtable

Translating vascular aging research from bench to bedside presents both significant opportunities and challenges. This paper summarizes insights from a roundtable discussion at the Artery 23 conference, featuring perspectives from basic science, clinical trials, regulation, and industry. The main co...

Full description

Saved in:
Bibliographic Details
Published inArtery research Vol. 30; no. 1; pp. 17 - 8
Main Authors Bianchini, Elisabetta, Roth, Lynn, Boutouyrie, Pierre, Badhwar, Smriti, Schwarz, Achim, Gemignani, Vincenzo, Bruno, Rosa Maria, Hametner, Bernhard, Park, Chloe, Pucci, Giacomo, Mozos, Ioana, Terentes-Printzios, Dimitrios, Climie, Rachel E., Guala, Andrea, Alastruey, Jordi, Mayer, Christopher C.
Format Journal Article
LanguageEnglish
Published Dordrecht Springer Netherlands 30.09.2024
Springer Nature B.V
BMC
Subjects
Aging
Bench to bedside
Bias
Biomarkers
Cardiovascular disease
Clinical medicine
Clinical trials
Conferences
Cooperation
Costs
Innovations
Medicine
Medicine & Public Health
Observational studies
Perspective
Pharmaceutical industry
Science
Translational science
Vascular aging
Veins & arteries
Translational science
Vascular aging
Bench to bedside
Online AccessGet full text

Cover

More Information
Summary:Translating vascular aging research from bench to bedside presents both significant opportunities and challenges. This paper summarizes insights from a roundtable discussion at the Artery 23 conference, featuring perspectives from basic science, clinical trials, regulation, and industry. The main conclusions of the discussion are as follows: basic science research must align with clinical relevance, using appropriate animal models and standardized measurement techniques. Pragmatic and registry-based clinical trials offer viable alternatives to traditional randomized controlled trials, facilitating real-world applicability. The regulatory landscape, particularly for software medical devices, must evolve to keep pace with technological advancements like artificial intelligence. Industry efforts focus on developing devices or solutions for vascular aging assessment and treatment strategies, yet face hurdles in large-scale adoption and reimbursement. Despite significant progress, the development of pharmacological interventions to mitigate vascular aging remains a critical need. This discussion underscores the importance of interdisciplinary collaboration to overcome barriers and translate scientific discoveries into clinical practice effectively.
ISSN:1876-4401
1872-9312
1876-4401
DOI:10.1007/s44200-024-00061-9